AFAvid Farhang Fagheh

Avid Farhang Fagheh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Avid Farhang Fagheh has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    High risk of drug toxicity in social isolation stress due to liver dysfunction: Role of oxidative stress and inflammation

    by Maziar Zahir, Siavash Shariatzadeh, Ayda Khosravi, Fatima Ahmed Alshaikh, Parichehr Moradi, Milad Ghaderi, Parsa Farsinejad, Parisa Afraz Louyeh, Saba Ilkhani, Pooria Nakhaei, et al.

    Background: Previous studies have shown that social isolation stress (SIS) could associate with several systemic diseases; however, the role of SIS on liver dysfunction has yet to be established. This study aimed to investigate the effect of SIS on liver function and possible drug toxicity through liver inflammation and oxidative stress.Methods: Male Naval Medical Research Institute mice in two groups of SIS and control were treated with typical anti‐depressant and anxiolytic agents including fluoxetine, norfluoxetine, desipramine, and imipramine in both groups. Then blood concentrations (or their active metabolites) of these drugs were assessed. Liver function test, including aspartate transaminase (AST), alanine aminotransferase (ALT), total bilirubin, and conjugated bilirubin), oxidative activity, inflammatory cytokines, and the gene expression of cytochrome P450 enzymes were assessed.Results: We observed that the liver enzymes including AST and ALT was slightly higher in SIS animals. The blood concentrations of fluoxetine, norfluoxetine, desipramine, and imipramine were significantly higher in SIS animals. The gene expression of CYP1A2, CYP2A6, CYP2C9, CYP2C29, and CYP2D were significantly decreased in SIS animals. Our results showed that SIS animals had significantly higher level of tumor necrosis factor‐α, interleukin‐1β, and interleukin‐6. SIS could significantly decrease the activity of antioxidant agent (Glutathione).Conclusion: We hypothesized that SIS could induce liver dysfunction and decrease the rate of drug clearance through liver inflammation and oxidative stress; therefore, the blood concentration of anti‐depressant/anxiolytic agents should closely monitor in SIS due to the high toxicity of these agents.


  • Open Access

    A Review of the Role of ERp57 in Cancerous and Non-Cancerous Cell Physiology and its Potential as a Therapeutic Target

    by Fatemeh Rahbar, Avid Farhang Fagheh, Ayda Khosravi, Siavash Shariatzadeh, Reza Akhavan-Sigari

    The protein ERp57 is a stress-responsive protein, mainly exists in the endoplasmic reticulum (ER), and a small amount in the cell membrane, cytoplasm, nucleus and mitochondria, which is involved in the signal transduction from the cell surface, the regulation process that occurs in the nucleus, and the formation of polymer protein complexes involved in DNA repair. Various degrees of ERp57 dysregulation has been observed in many types of non-communicable diseases especially in cancers. Previous studies showed that the expression of ERp57 could play a key role in occurrence and development of cancers such as breast cancer, gastric cancer, ovarian cancer, etc.; in addition, it has been suggested to play a pivotal role in disease progression of non-cancerous diseases such as neurodegeneration, liver disease, kidney disease, intestinal irritability syndrome and airway hypersensitivity. Thus, abnormal expression of ERp57 could be used as promising biomarker for cancer diagnosis and prognosis based on the previous studies. In this regard, current study was aimed to review the literature, which have been elucidate the role of ERp57 protein expression in both non-cancer and cancer disease. Overall, most studies have shown that inhibiting/knocking out of ERp57 could inhibit the cell proliferation and also induce apoptosis in both human cancerous and non-cancerous cells. Also, it has been suggested that the overexpression of ERp57 could intensify the cancer development. Therefore, it could be hypothesized that targeting of ERp57 might be a potential treatment in cancerous and non-cancerous diseases.